Evaluation of plasma and urinary salbutamol levels in COPD.
OBJECTIVE
To evaluate the use of trough plasma salbutamol and overnight urinary salbutamol excretion in the assessment of nebulised salbutamol delivery in patients with chronic obstructive pulmonary disease (COPD).


METHODS
Twenty in-patients with COPD receiving nebulised salbutamol, age 69.7 years, FEV1 38.1% predicted, were studied on two consecutive days, receiving four 2.5 mg doses of nebulised salbutamol on day 1 and four 5 mg doses of nebulised salbutamol on day 2, the first dose at 8.00 h the last dose at 22.00 h. Salbutamol delivery was assessed after the last dose by trough plasma salbutamol 8.00 h and overnight urinary excretion of salbutamol (22.00-8.00 h).


RESULTS
Levels of urinary salbutamol were detectable in all 20 patients at both doses, whereas for plasma salbutamol detectable levels were only found in 16/20 cases at the 2.5 mg dose and in all cases at the 5 mg dose. For overnight urinary salbutamol (microgram x 10 h-1 n = 20) the results were 141 for 2.5 mg and 249 for 5 mg. The dose ratio for urinary salbutamol between 2.5 mg and 5 mg doses was 1.83. Results for plasma salbutamol (ng/ml, n = 16) were 1.58 at 2.5 mg and 2.43 at 5 mg: dose ratio (geometric mean) 1.49.


CONCLUSIONS
Overnight urinary salbutamol provides a simple and effective measure of nebulised salbutamol delivery in patients with COPD, which would be suitable for studying nebuliser performance and compliance.
Clark
D J
DJ
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, UK.
Tan
K S
KS
Lipworth
B J
BJ
D000280:Administration, Inhalation; D000368:Aged; D000420:Albuterol / Q000097:blood* / Q000652:urine*; D000704:Analysis of Variance; D001993:Bronchodilator Agents / Q000097:blood* / Q000652:urine*; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000378:metabolism*; D008297:Male; D014018:Tissue Distribution
D001993:Bronchodilator Agents; D000420:Albuterol